Many well-designed multi-national trials have shown that ICI plus chemotherapy substantially improves PFS and OS compared with chemotherapy alone in advanced NSCLC, irrespective of programmed cell death-ligand 1 (PD-L1) expression levels [9–11]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.